<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000346492">
  <TermName>Ro 50-3821</TermName>
  <TermDefinition>
    <DefinitionText>A substance that is being studied in the treatment of anemia in patients who are receiving chemotherapy. It is a form of erythropoietin (a substance produced in the kidneys that stimulates the production of red blood cells) that has been changed in the laboratory. Also called methoxypolyethylene glycol epoetin beta.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <SpanishTermName>Ro 50-3821</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de la anemia en los pacientes que reciben quimioterapia. Es una forma de eritropoyetina (una sustancia producida en los riñones que estimula la producción de glóbulos rojos) que se ha alterado en el laboratorio. También se llama metoxipolietilenglicol-epoetina beta.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2003-11-20</DateFirstPublished>
  <DateLastModified>2007-05-17</DateLastModified>
</GlossaryTerm>
